AVEO Enters into Research And Exclusive Option Agreement With Ophthotech For Tivozanib (VEGF inhibitor) For The Treatment Of Ocular Diseases

By: via Benzinga
AVEO Oncology (NASDAQ: AVEO) today announced that it has entered into a research and exclusive option agreement with Ophthotech ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.